Safety of sildenafil citrate: Review of 67 double-blind placebo-controlled trials and the postmarketing safety database

International Journal of Clinical Practice

Volumn 64, Issue 2, 2010, Pages 240-255

  Giuliano, F ^a   Jackson, G ^b   Montorsi, F ^c   Martin Morales, A ^d   Raillard, P ^e  

^a RAYMOND POINCARÉ HOSPITAL   (France)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d Serv Urol   (Spain)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALKALINE PHOSPHATASE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMITRIPTYLINE; AMYL NITRATE; APHRODISIAC AGENT; APOMORPHINE; ASPARTATE AMINOTRANSFERASE; CIMETIDINE; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DOXAZOSIN; ERYTHROMYCIN; FLUPHENAZINE; GLYCERYL TRINITRATE; KETOCONAZOLE; NITRIC ACID DERIVATIVE; NITRIC OXIDE DONOR; NORTRIPTYLINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; PSYCHOTROPIC AGENT; RITONAVIR; SILDENAFIL; TAMSULOSIN; TERAZOSIN; TRAZODONE; UNINDEXED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLURRED VISION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CYANOPSIA; DATA BASE; DIZZINESS; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG METABOLISM; DRUG MISUSE; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; ERECTILE DYSFUNCTION; ERYTHEMA; EYE DISEASE; FLUSHING; HEARING LOSS; HEART INFARCTION; HEART PALPITATION; HOT FLUSH; HUMAN; HYPERTHERMIA; HYPOTENSION; KIDNEY FUNCTION; LIVER FUNCTION; LOW DRUG DOSE; MALAISE; MYALGIA; NAUSEA; NON ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY; NOSE CONGESTION; OPTIC NERVE DISEASE; PRIAPISM; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; UREA NITROGEN BLOOD LEVEL; VISUAL DISORDER;

AGED; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ERECTILE DYSFUNCTION; HEARING DISORDERS; HUMANS; KIDNEY DISEASES; LIVER DISEASES; MALE; MIDDLE AGED; OVERDOSE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PRIAPISM; PRODUCT SURVEILLANCE, POSTMARKETING; PURINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONES; TREATMENT OUTCOME;

EID: 72449123274     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02254.x     Document Type: Review

References (78)

1. Dinsmore WW, Hodges M, Hargreaves C et al. Sildenafil citrate (VIAGRA) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urology 1999 53 : 800 805.
2. Montorsi F, McDermott TED, Morgan R et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 1999 53 : 1011 1018.
3. Goldstein I, Lue TF, Padma-Nathan H et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998 338 : 1397 1404.
4. Becher E, Tejada Noriega A, Gomez R, Decia R. Sildenafil citrate (Viagra) in the treatment of men with erectile dysfunction in southern Latin America: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, flexible-dose escalation study. Int J Impot Res 2002 14 (Suppl. 2 S33 41.
5. Glina S, Bertero E, Claro J et al. Efficacy and safety of flexible-dose oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction in Brazilian and Mexican men. Int J Impot Res 2002 14 (Suppl. 2 S27 32.
6. Gomez F, Davila H, Costa A et al. Efficacy and safety of oral sildenafil citrate (Viagra) in the treatment of male erectile dysfunction in Colombia, Ecuador, and Venezuela: a double-blind, multicenter, placebo-controlled study. Int J Impot Res 2002 14 (Suppl. 2 S42 7.
7. Levinson IP, Khalaf IM, Shaeer KZ, Smart DO. Efficacy and safety of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in Egypt and South Africa. Int J Impot Res 2003 15 (Suppl. 1 S25 9.
8. Osegbe DN, Shittu OB, Aghaji AE et al. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in Nigerian men. Int J Impot Res 2003 15 (Suppl. 1 S15 8.
9. Tan HM, Moh CL, Mendoza JB et al. Asian sildenafil efficacy and safety study (ASSESS-1): a double-blind, placebo-controlled, flexible-dose study of oral sildenafil in Malaysian, Singaporean, and Filipino men with erectile dysfunction. The Assess-1 Study Group. Urology 2000 56 : 635 640.
10. Chen KK, Hsieh JT, Huang ST et al. ASSESS-3: a randomised, double-blind, flexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan. Int J Impot Res 2001 13 : 221 229.
11. Stuckey BG, Jadzinsky MN, Murphy LJ et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2003 26 : 279 284.
12. Laties AM, Sharlip I. Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. J Sex Med 2006 3 : 12 27.
13. Salonia A, Rigatti P, Montorsi F. Sildenafil in erectile dysfunction: a critical review. Curr Med Res Opin 2003 19 : 241 262.
14. ®) is effective and well tolerated for treating erectile dysfunction of psychogenic or mixed aetiology. Int J Clin Pract 2000 54 : 561 566.
15. ®. Summary of Product Characteristics, Sildenafil Citrate. Sandwich, Kent : UK Pfizer Limited, 2008.
16. ®) in clinical populations: an update. Urology 2002 60 : 12 27.
17. ®). Urology 2002 60 (Suppl. 2B 67 90.
18. IMS commissioned report and 2.7.4. Summary of Clinical Safety. Data on File. New York, NY : Pfizer Inc, 2008.
19. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil - review of the literature. Eur J Med Res 2002 7 : 435 446.
20. Campbell HE. Clinical monograph for drug formulary review: erectile dysfunction agents. J Manag Care Pharm 2005 11 : 151 171.
21. Brock GB, McMahon CG, Chen KK et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002 168 : 1332 1336.
22. Hellstrom WJ, Gittelman M, Karlin G et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002 23 : 763 771.
23. Hellstrom WJ, Gittelman M, Karlin G et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003 61 : 8 14.
24. Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. BJU Int 2004 93 : 796 801.
25. Cheng E. Real-life safety and efficacy of vardenafil in the treatment of erectile dysfunction-results from 30,010 U.S. patients. J Sex Med 2007 4 : 432 439.
26. Hazell L, Boshier A, Harris S et al. An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischaemic heart disease. BJU Int 2007 99 : 387 393.
27. ®): an updated perspective. Urology 2006 68 : 47 60.
28. Kim CM, Kim YS, Sunwoo S et al. Post-marketing surveillance study of the efficacy and safety of vardenafil among patients with erectile dysfunction in primary care. Int J Impot Res 2007 19 : 393 397.
29. Mittleman MA, Maclure M, Lewis MA et al. Cardiovascular outcomes among sildenafil users: results of the International Men's Health study. Int J Clin Pract 2008 62 : 367 373.
30. van Ahlen H, Zumbe J, Stauch K, Landen H. The real-life safety and efficacy of vardenafil: an international post-marketing surveillance study - results from 29,358 German patients. J Int Med Res 2005 33 : 337 348.
31. Feldman HA, Goldstein I, Hatzichristou DG et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994 151 : 54 61.
32. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999 84 : 50 6.
33. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 2005 165 : 1363 1369.
34. Sobel RE, Reynolds RF. Integrating evidence from multiple sources to evaluate post-approval safety: an example of sildenafil citrate and cardiovascular events. Curr Med Res Opin 2008 24 : 1861 1868.
35. Council of Europe. Opinion on Parliamentary Assembly Recommendation 1673. 2004. Counterfeiting: problems and solutions. 51st Meeting of the European Committee on Crime Problems/Committee of Experts on the Operation of European Conventions in the Penal Field (PC-OC) 2006. http://www.coe.int/t/e/legal- affairs/legal-co-operation/transnational-criminal-justice/2-pc-oc/PCOC%20(2006) %2004%20Rev%20E.asp [Accessed 3 March 2006].
36. Blok-Tip L, Vogelpoel H, Vredenbregt M et al. Counterfeits and imitations of Viagra and Cialis tablets: trends and risks to public health. A survey of the analysis carried out at the Dutch National Institute for Public Health and the Environment in the time period 2000-2004. RIVM report 2005. http://www.rivm.nl/bibliotheek/rapporten/267041001.pdf [Accessed 28 November 2007].
37. WHO. Drug Dictionary, 2002. 2nd Quarter. Uppsala, Sweden : Uppsala Monitoring Centre.
38. Carson C, Siegel R, Orazem J. Sildenafil citrate treatment for erectile dysfunction: rate of adverse events decreases over time. J Urol 2002 167 (Suppl. 179.
39. Wespes E, Amar E, Hatzichristou D et al. EAU guidelines on erectile dysfunction: an update. Eur Urol 2006 49 : 806 815.
40. ®) in patients with erectile dysfunction. Urology 2002 60 : 28 38.
41. Bacon CG, Mittleman MA, Kawachi I et al. A prospective study of risk factors for erectile dysfunction. J Urol 2006 176 : 217 221.
42. Kupelian V, Link CL, McKinlay JB. Association between smoking, passive smoking, and erectile dysfunction: results from the Boston Area Community Health (BACH) Survey. Eur Urol 2007 52 : 416 422.
43. Kupelian V, Shabsigh R, Araujo AB et al. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol 2006 176 : 222 226. (Pubitemid 43815376)
44. Millett C, Wen LM, Rissel C et al. Smoking and erectile dysfunction: findings from a representative sample of Australian men. Tob Control 2006 15 : 136 139.
45. Ponholzer A, Temml C, Mock K et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 2005 47 : 80 5.
46. Riedner CE, Rhoden EL, Ribeiro EP, Fuchs SC. Central obesity is an independent predictor of erectile dysfunction in older men. J Urol 2006 176 : 1519 1523.
47. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007 120 : 151 157.
48. Feldman HA, Johannes CB, Derby CA et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 2000 30 : 328 338.
49. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004 171 : 2341 2345.
50. Mittleman MA, Maclure M, Glasser DB. Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate. Am J Cardiol 2005 96 : 443 446.
51. Mittleman MA, Glasser DB, Orazem J. Clinical trials of sildenafil citrate (Viagra) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo. Int J Clin Pract 2003 57 : 597 600.
52. Blonde L. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials. Curr Med Res Opin 2006 22 : 2111 2120.
53. Boulton AJ, Selam JL, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 2001 44 : 1296 1301.
54. Buranakitjaroen P, Mangklabruks A, Leungwattanakij S et al. Efficacy and safety of sildenafil in Asian males with erectile dysfunction and cardiovascular risk. J Med Assoc Thai 2007 90 : 1100 1108.
55. Pickering TG, Shepherd AM, Puddey IB et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am J Hypertens 2004 17 : 1135 1142.
56. Katz SD, Parker JD, Glasser DB et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. Am J Cardiol 2005 95 : 36 42.
57. Olsson AM, Persson CA. Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease. Int J Clin Pract 2001 55 : 171 176.
58. Bialecki ES, Bridges KR. Sildenafil relieves priapism in patients with sickle cell disease. Am J Med 2002 113 : 252.
59. Gorkin L, Hvidsten K, Sobel RE, Siegel R. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int J Clin Pract 2006 60 : 500 503.
60. Mukherjee B, Shivakumar T. A case of sensorineural deafness following ingestion of sildenafil. J Laryngol Otol 2007 121 : 395 397.
61. Muirhead GJ, Rance DJ, Walker DK, Wastall P. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. Br J Clin Pharmacol 2002 53 (Suppl. 1 13S 20S.
62. Rosas SE, Wasserstein A, Kobrin S, Feldman HI. Preliminary observations of sildenafil treatment for erectile dysfunction in dialysis patients. Am J Kidney Dis 2001 37 : 134 137.
63. Chen J, Mabjeesh NJ, Greenstein A et al. Clinical efficacy of sildenafil in patients on chronic dialysis. J Urol 2001 165 : 819 821.
64. Seibel I, Poli De Figueiredo CE, Teloken C, Moraes JF. Efficacy of oral sildenafil in hemodialysis patients with erectile dysfunction. J Am Soc Nephrol 2002 13 : 2770 2775.
65. Mahon A, Sidhu PS, Muir G, Macdougall IC. The efficacy of sildenafil for the treatment of erectile dysfunction in male peritoneal dialysis patients. Am J Kidney Dis 2005 45 : 381 387.
66. Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol 2005 96 : 42M 6M.
67. Narayan P, Gagnier P, Doyle C. Concomitant use of sildenafil with tamsulosin or terazosin: a retrospective safety evaluation (abstract). J Urol 2004 171 (Suppl. 4 357.
68. De Rose AF, Giglio M, Traverso P et al. Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. Int J Impot Res 2002 14 : 50 3.
69. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007 51 : 1717 1723.
70. Lue TF, Giuliano F, Montorsi F et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004 1 : 6 23.
71. European Medicines Agency. VIAGRA European Public Assessment Report (EPAR), revision 11. European Public Assessment Reports (EPAR) for authorised medicinal products for human use 03/09/2008. http://www.emea.europa.eu/ humandocs/Humans/EPAR/viagra/viagra.htm [Accessed 19 September 2008].
72. Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005 353 : 2148 2157. (Pubitemid 41653106)
73. ® (sildenafil citrate): results of the international men's health study. Eur Urol 2005 4 (Suppl. 3 137.
74. Boolell M, Allen MJ, Ballard SA et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996 8 : 47 52.
75. McMurray JG, Feldman RA, Auerbach SM et al. Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. Ther Clin Risk Manag 2007 3 : 975 981.
76. Smith KM, Romanelli F. Recreational use and misuse of phosphodiesterase 5 inhibitors. J Am Pharm Assoc 2005 45 : 63 72.
77. Romanelli F, Smith KM. Recreational use of sildenafil by HIV-positive and -negative homosexual/bisexual males. Ann Pharmacother 2004 38 : 1024 1030.
78. Sugar SJ. Reply to 'Viagra: the risks of recreational use'. Am J Med 2006 119 : 92 3.